glp 1 2025 GLP-1 Shortage = Over GLP-1 Pipeline Update: May 2025

However, Medicare Part D may cover these medications for type 2 diabetes or cardiovascular risk reduction (Wegovy received FDA approval for cardiovascular benefits in March 2024)

Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function

If a pharmacy is out of Ozempic and suggests a "just as good" alternative from an unfamiliar manufacturer, politely decline and try another pharmacy

The drug was initially approved by the U.S

Eligibility typically includes individuals with a body mass index (BMI) of 30 or higher , or a BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol

Employers offering weight-loss coverage rose in 2026 from 17% in 2024 Canadian employers are broadening access to glucagon-like peptide-1 (GLP-1) drugs for weight loss, with the share offering that coverage rising to 37 percent in 2026 from 17 percent in 2024